CAJ | 학술논문

手术联合放化疗是肺癌常规治疗手段，但术后复发十分常见，患者死亡率高，生命质量较低。而术后免疫治疗可充分调动患者的机体防御机制，激活免疫细胞，杀灭残留癌细胞。目前关于肺癌免疫治疗的研究成果主要包括4大类：过继性免疫治疗、树突状细胞疫苗、非特异性抗原免疫治疗和抗原特异性疫苗。这些研究成果均表明肺癌术后免疫治疗干预可有效减少癌细胞残留，降低术后复发率，延长患者生存时间，显著改善预后，值得临床推广。
수술연합방화료시폐암상규치료수단，단술후복발십분상견，환자사망솔고，생명질량교저。이술후면역치료가충분조동환자적궤체방어궤제，격활면역세포，살멸잔류암세포。목전관우폐암면역치료적연구성과주요포괄4대류：과계성면역치료、수돌상세포역묘、비특이성항원면역치료화항원특이성역묘。저사연구성과균표명폐암술후면역치료간예가유효감소암세포잔류，강저술후복발솔，연장환자생존시간，현저개선예후，치득림상추엄。
Surgery in combination with chemotherapy and radiotherapy is the standard of lung cancer treatment,but postoperative recurrence is very common which usually leads to higher mortality and lower life quality. Immunotherapy on post-operative patients fully mobilizes the body's defense mechanisms,activates the immune cells,and kills residual cancer cells. Current research on lung cancer immunotherapy mainly includes four categories:adoptive immunotherapy,dendritic cell vaccine,non-specific antigen immune therapy and anti-gen-specific vaccine. These studies show lung cancer immunotherapy intervention can effectively reduce postop-erative residual cancer cells,reduce postoperative recurrence rate,prolong survival,significantly improve the prognosis,and is worth spreading in clinical practice.